Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
ELVN holding history
Enliven Therapeutics, Inc. in every 13F filed by Commodore Capital LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ELVN overviewAll 13F holders of ELVNFull Q2 2026 holdings
- Shares (Q2 2026)
- 3,275,000
- Value
- $166.2M
- % of portfolio
- 9.9%
- Quarters held
- 15
- Since Q4 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 3,275,000 | $166.2M | 9.9% | 00.0% | Unchanged | Holders |
| Q1 2026 | 3,275,000 | $128.4M | 7.4% | −1,417,809−30.2% | Reduced | Holders |
| Q4 2025 | 4,692,809 | $72.3M | 4.8% | 00.0% | Unchanged | Holders |
| Q3 2025 | 4,692,809 | $96.1M | 4.7% | 00.0% | Unchanged | Holders |
| Q2 2025 | 4,692,809 | $94.1M | 6.6% | +17,809+0.4% | Added | Holders |
| Q1 2025 | 4,675,000 | $92.0M | 6.8% | +470,000+11.2% | Added | Holders |
| Q4 2024 | 4,205,000 | $94.6M | 6.9% | +105,000+2.6% | Added | Holders |
| Q3 2024 | 4,100,000 | $104.7M | 6.5% | +126,755+3.2% | Added | Holders |
| Q2 2024 | 3,973,245 | $92.9M | 6.3% | 00.0% | Unchanged | Holders |
| Q1 2024 | 3,973,245 | $69.9M | 4.7% | +1,071,429+36.9% | Added | Holders |
| Q4 2023 | 2,901,816 | $40.2M | 3.5% | 00.0% | Unchanged | Holders |
| Q3 2023 | 2,901,816 | $39.6M | 4.6% | +553,544+23.6% | Added | Holders |
| Q2 2023 | 2,348,272 | $47.9M | 5.4% | +616,907+35.6% | Added | Holders |
| Q1 2023 | 1,731,365 | $37.9M | 5.8% | −763,429−30.6% | Reduced | Holders |
| Q4 2022 | 2,494,794 | $10.2M | 1.5% | +2,494,794 | New | Holders |